We utilized NSCLC PC9 cells, which harbor an activating mutation of EGFR (mutEGFR) that renders them highly sensitive to the cytotoxic effects of EGFR TKIs such as erlotinib, and wild-type (WT) EGFR H522 cells that are modestly sensitive to TKIs. Here, EGFR is linked to non-small cell lung carcinoma.